简体|繁體
Introduction

Essex Bio-Technology Limited (“EssexBio Group” and the “Company”) was incorporated in the Cayman Islands on 31st July, 2000 and has been listed on the Stock Exchange of Hong Kong since 27th June, 2001.
 

Essex specializes in biopharmaceutical drug development based on recombinant DNA technology. It is principally engaged in the manufacture and sale of biopharmaceutical products for the treatment and healing of surface wounds and eye wounds. The Group also engaged in the research and development of bFGF products for new indications, as well as other ophthalmic pharmaceutical projects.
 

A series of genetically engineered bio-pharmaceutical drugs have been successfully developed and three of them were classified as State-level Category I new drugs. The main brands of the Company's products are Beifuji, Beifushu and Beifuxin.